Cadila Healthcare advances after securing USFDA nod

Cadila Healthcare rose 1.11% to Rs 381.50 at 09:46 IST on BSE after the company announced that it has received final approval from the USFDA for Triamterene and Hydrochlorothiazide Tablets USP.

The announcement was made on Saturday, 30 June 2018.

Meanwhile, the S&P BSE Sensex was down 118.91 points, or 0.34% to 35,304.57.

On the BSE, 16,000 shares were traded in the counter so far compared with average daily volumes of 1.10 lakh shares in the past two weeks. The stock had hit a high of Rs 384.85 and a low of Rs 379.50 so far during the day. The stock hit a record high of Rs 554.20 on 25 July 2017. The stock hit a 52-week low of Rs 341.65 on 22 May 2018.

The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.

Zydus Cadila has received the final approval from the USFDA to market Triamterene and Hydrochlorothiazide Tablets USP in strengths of 37.5 mg/25 mg and 75 mg/SO mg. It is used for the treatment of high blood pressure. This combination drug is used by patients who have developed or are at risk for having low potassium levels on hydrochlorothiazide. It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has more than 195 approvals and has so far filed over 320 ANDAs since the commencement ofthe filing process in FY 2003-04, Zydus Cadila said.

On a consolidated basis, net profit of Cadila Healthcare rose 53.26% to Rs 590.80 crore on 31.03% rise in net sales to Rs 3152.70 crore in Q4 March 2018 over Q4 March 2017.

Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News